Stress causes “ulcers and heartburn”, said Lex in the FT. “Now the treatment of these afflictions is causing anxiety for investors.”
Shares of GlaxoSmithKline, Sanofi and the new GSK spin-off, Haleon, all fell sharply last week – shedding tens of billions of dollars – as investors took fright over the reported carcinogenic risk posed by the over-the-counter drug Zantac. Damages, if awarded, could be as high as $45bn, according to Morgan Stanley. And since rights of the over-the-counter version of Zantac have been transferred repeatedly, “it is unclear where any liabilities might sit”.
The issue of whether Zantac (the brand name for a drug called ranitidine) generates a probable carcinogen called NDMA has been building in the background for years, said Julianna Tatelbaum on CNBC: the drug was formally pulled from shelves in 2020, but legal proceedings have focused minds. The first of more than 2,000 cases begins in the US this month.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The pharmas believe their legal position is strong, said Fierce Pharma. “The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk,” stated GSK. Even if that risk is demonstrated, it will be “tough” to prove that the companies “knew of the danger and failed to warn customers” before withdrawing Zantac.
The litigation creates an awkward situation for GSK and the recently floated Haleon, said Alistair Osborne in The Times. If liability becomes an issue, it could mean “an unseemly legal dust-up between two companies that were in the same group four weeks ago”.
Precedent suggests investors should certainly remain wary, said Lex. The Bayer/Roundup weedkiller saga – which ultimately cost the German pharma at least $16bn – “shows it is easy to draw a line under claims prematurely”.
-
France’s ‘red hands’ trial highlights alleged Russian disruption operationsUNDER THE RADAR Attacks on religious and cultural institutions around France have authorities worried about Moscow’s effort to sow chaos in one of Europe’s political centers
-
The 8 best dark comedies of the 21st centuryFrom Santa Claus to suicide terrorism, these movies skewered big, taboo subjects
-
Codeword: October 30, 2025The Week's daily codeword puzzle
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
The quest to defy ageingThe Explainer Humanity has fantasised about finding the fountain of youth for millennia. How close are we now?
-
The battle of the weight-loss drugsTalking Point Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills
-
An insatiable hunger for proteinFeature Americans can't get enough of the macronutrient. But how much do we really need?
-
Deadly fungus tied to a pharaoh's tomb may help fight cancerUnder the radar A once fearsome curse could be a blessing
-
'Poo pills' and the war on superbugsThe Explainer Antimicrobial resistance is causing millions of deaths. Could a faeces-filled pill change all that?
-
RFK Jr.: A new plan for sabotaging vaccinesFeature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root causeFeature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
